Should perform testing for:
• t(9;22)(q34;q11.2); BCR-ABL1
May perform testing for:
Should perform testing for:
May perform:
Flow cytometry panel should include sufficient markers to identify early T-cell precursor (ETP)
May perform:
Mutational analysis for NOTCH1 and/or FBXW7
Should perform:
FLT3-ITD mutation
May perform:
Mutational analysis that includes (but is not limited to): IDH1, IDH2, TET2, WT1, DNMT3A, and/or TP53
Should perform:
▪ Rapid detection of PML-RARA
▪ Coagulation studies to evaluate for DIC
t(8;21)(q22;q22.1); RUNX1-RUNX1T1 or inv16(p13.1q22)/ t(16;16)(p13.1;q22); CBFB-MYH11
Should perform:
KIT mutation
May perform:
KIT mutation
Should perform:
Mutational analysis for NPM1, CEBPA and RUNX1
Should perform testing for:
For all patients with suspected leukemia:
If a CSF sample is collected at the time of intrathecal therapy or for other clinical indications, should perform:
May perform: CSF flow cytometry
Should use the current WHO terminology for the final diagnosis and classification of acute leukemia.